Patents Examined by Marianne P. Allen
  • Pharmaceutical preparation stably comprising CD147 monoclonal antibody
    Patent number: 11027016
    Abstract: Disclosed is a pharmaceutical preparation comprising a CD147 monoclonal antibody, a buffer, a protein protectant and a surfactant. The pharmaceutical preparation can maintain the stability of the CD147 monoclonal antibody over a long period of time. Also disclosed are the use of the pharmaceutical preparation in the preparation of a drug for treating CD147-related diseases, in particular non-small cell lung cancer, and a method for preparing the pharmaceutical preparation.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: June 8, 2021
    Inventor: Xiaochun Chen
  • Fusion polypeptides and methods of use
    Patent number: 11020454
    Abstract: Provided are fusion polypeptides comprising fragments from a first and a second FGF family member, nucleic acids encoding the fusion polypeptides, vectors and host cells containing the same, and methods of making and using such compositions in the treatment of FGF-related diseases, disorders, and conditions.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: June 1, 2021
    Assignee: PROSIT SOLE BIOTECHNOLOGY (BEIJING) CO. LTD
    Inventors: Hongyu Liu, Mingzhi Zhao, Hetong Sun
  • Endoglin polypeptides and uses thereof
    Patent number: 10981972
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a truncated, ligand-binding portion of the extracellular domain of endoglin (ENG) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: April 20, 2021
    Assignee: Acceleron Pharma Inc.
    Inventors: Asya Grinberg, Roselyne Castonguay, Eric Werner, Ravindra Kumar
  • Heterodimeric antibodies that bind fibroblast activation protein
    Patent number: 10982006
    Abstract: The present invention relates to novel antigen binding domains and heterodimeric antibodies that bind Fibroblast Activation Protein (FAP).
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: April 20, 2021
    Assignee: Xencor, Inc.
    Inventors: John Desjarlais, Alex Nisthal, Seung Chu
  • Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
    Patent number: 10967049
    Abstract: Fusion proteins comprising cytokines, particularly insulin-like growth factor-1 (IGF-1) and variants thereof, epidermal growth factor (EGF), and other ligands to the EGF receptor, are provided. The fusion proteins further comprise SEQ ID NO:1 or other segments having lysine, glutamic acid, or aspartic acid residues. Uses for the fusion proteins are also provided.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: April 6, 2021
    Assignee: IGF Oncology, LLC
    Inventor: Hugh McTavish
  • Methods and compositions for the prevention and treatment of surgical adhesions
    Patent number: 10934355
    Abstract: Aspects of the present disclosure include methods of treating a subject to reduce adhesion formation, the method comprising administering to a subject in need of thereof an agent that that targets adhesion-formation by injured mesothelial cells. The agent can act at a variety of checkpoints in the development of adhesions by injured mesothelial cells, including: targeting the injured mesothelial cells for destruction, recruiting inflammatory macrophages to the site of adhesion, preventing neutrophil recruitment to the site of adhesion, and/or inhibiting the expression or activity of a gene product whose expression is induced in the injured mesothelial cells. Compositions and kits for performing the methods are also provided.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: March 2, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jonathan Tsai, Nathaniel Fernhoff, Rahul Sinha, Yuval Rinkevich, Irving L. Weissman
  • Method for treating chemotherapy-induced male infertility
    Patent number: 10925928
    Abstract: A method of ameliorating, inhibiting, preventing, or reducing male infertility in a subject undergoing or in need of chemotherapy by administering to the subject a granulocyte colony-stimulating factor in a protective amount, prior to, during or after administration of one or more chemotherapeutic agents to the subject.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: February 23, 2021
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Brian P. Hermann
  • Antibodies to IL-6 and use thereof
    Patent number: 10913794
    Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: February 9, 2021
    Assignee: VITAERIS INC.
    Inventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T. L. Smith
  • FGF21 mimetic antibodies and uses thereof
    Patent number: 10899844
    Abstract: The present disclosure relates to monoclonal antibodies and antigen-binding fragments thereof that bind to human ?-klotho, and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: January 26, 2021
    Assignee: Novartis AG
    Inventors: Regis Cebe, Stephane Olland, David Langdon Yowe
  • EGFL6 specific monoclonal antibodies and methods of their use
    Patent number: 10875912
    Abstract: Isolated or recombinant anti-EGFL6 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: December 29, 2020
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Ningyan Zhang, Zhiqiang An, Anil K. Sood
  • TRPV3 agonists for the treatment of skin conditions
    Patent number: 10864152
    Abstract: Described are methods and uses of TRPV3 agonists for the treatment of conditions associated with TRPV3 pathophysiology such as acne, psoriasis, dermatitis, would healing, the inhibition of hair growth, anxiety or depression. Peptides comprising all or part of the C-terminal portion of soricidin are shown to activate TRPV3 cation channel activity and/or promote wound healing in keratinocytes.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: December 15, 2020
    Assignee: Soricimed Biopharma Inc.
    Inventor: John M. Stewart
  • Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
    Patent number: 10858418
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: December 8, 2020
    Assignee: Ablynx N.V.
    Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
  • EGF(A) analogues with fatty acid substituents
    Patent number: 10822385
    Abstract: The invention relates to compounds derived from the EGF(A) domain of LDL-R, in particular compounds comprising a peptide analogue of the wild-type EGF(A) (LDL-R(293-332)) sequence and at least one substituent comprising at least one fatty acid group. The invention also relates to a pharmaceutical composition thereof and use a medicament. The novel EGF(A) compounds of the invention are useful as treatment e.g. in the field of cholesterol lowering, dyslipidaemia and cardiovascular disease.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: November 3, 2020
    Assignee: Novo Nordisk A/S
    Inventors: Jianhe Chen, Jesper F. Lau, Janos Tibor Kodra, Birgit Wieczorek, Lars Linderoth, Henning Thoegersen, Salka Elboel Rasmussen, Patrick William Garibay
  • Heparin-associated polypeptides and uses thereof
    Patent number: 10821155
    Abstract: Described herein are therapeutic compositions comprising heparin-associated polypeptides useful for the treatment of soft-tissue and muscle diseases, disorders, and injuries.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: November 3, 2020
    Assignee: Juvena Therapeutics, Inc.
    Inventors: Hanadie Yousef, Thach Mai, Jeremy O'Connell
  • Fusion protein comprising antifreeze protein and human epidermal growth factor with increased anti-oxidant activity and skin cell proliferation effect and cosmetic composition for anti-wrinkle comprising the same as effective component
    Patent number: 10815284
    Abstract: A fusion protein has the amino acid sequence of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8. A composition having the fusion protein may improve skin wrinkle with increased anti-oxidant activity and skin cell proliferation effect. It can be advantageously used as a raw material of a functional cosmetic having an excellent skin regeneration effect like improvement of skin wrinkles and skin whitening.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: October 27, 2020
    Assignees: NEXGEN BIOTECHNOLOGIES, INC.
    Inventors: Sun Kyo Lee, Tae Hyun Kim, Seong Ran Lee, Han Bong Ryu, Tae Won Choi, Hyeong Il Kwon, Woo Yeon Roh
  • Methods for treating vascular leak syndrome and cancer
    Patent number: 10815300
    Abstract: Disclosed are methods for treating Vascular Leak Syndrome and preventing cancer metastasis. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, sepsis, cancer or the presence of pathogens.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: October 27, 2020
    Assignee: AERPIO PHARMACEUTICALS, INC.
    Inventors: Kevin Peters, Robert Shalwitz
  • Antagonist antibodies that bind to human TGFB1, TGFB2 and to TGFB3 and their use for the treatment of lung fibrosis
    Patent number: 10766956
    Abstract: The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: September 8, 2020
    Assignee: UCB BIOPHARMA SRL
    Inventors: Helene Bon, Joanne Elizabeth Compson, Kate Louise Dixon, Carl Brendan Doyle, Mark Ellis, Maria Margarida Gouveia Sancho, Raymond Anthony Jupp, Lara Kevorkian, Daniel John Lightwood, Diane Marshall, Andrew Charles Payne, Joseph Michael David Rastrick, Monika-Sarah Schulze, Alison Turner, Kerry Louise Tyson
  • Antibodies to IL-6 and use thereof
    Patent number: 10759853
    Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: September 1, 2020
    Assignee: Alderbio Holdings LLC
    Inventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T. L. Smith
  • IGF-1R antibody and its use for the diagnosis of cancer
    Patent number: 10753937
    Abstract: The present disclosure relates to IGF-IR (insulin like growth factor receptor-1) antibodies characterized by CDR sequences a, to be used in detection methods of IGF-IR expressing tumoral cells.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: August 25, 2020
    Assignee: Pierre Fabre Medicament
    Inventor: Alexandra Jouhanneaud
  • Soluble human ST-2 antibodies and assays
    Patent number: 10745484
    Abstract: Provided herein are antibodies and antigen-binding antibody fragments that bind to human soluble Growth Stimulation-Expressed Gene 2 (ST2) protein, kits containing these antibodies and antibody fragments, and methods of using these antibodies and antibody fragments.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: August 18, 2020
    Assignee: Critical Care Diagnostics, Inc.
    Inventor: James V. Snider